longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

DBS Sticks to Their Hold Rating for Johnson & Johnson (JNJ)

Tip Ranks
Sep 11, 2026 at 04:55 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

In a report released today, Nico Chen from DBS maintained a Hold rating on Johnson & Johnson, with a price target of $270.00. According to TipRanks, Chen is a 4-star analyst with an average return of 8.6% and a 57.53% success rate. Chen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Johnson & Johnson, and Merck & Company. Johnson & Johnson has an analyst consensus of Strong Buy, with a price target consensus of $286.61.

In a report released today, Nico Chen from DBS maintained a Hold rating on Johnson & Johnson, with a price target of $270.00.

According to TipRanks, Chen is a 4-star analyst with an average return of 8.6% and a 57.53% success rate. Chen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Johnson & Johnson, and Merck & Company.

Johnson & Johnson has an analyst consensus of Strong Buy, with a price target consensus of $286.61.

Login to unlock469characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

  • Feb 11, 2026 at 01:54 AMWhen AI enters hospitals, risks such as "surgical errors and misidentification of organs" also arise

Related Stocks

Johnson & Johnson

Johnson & Johnson

USJNJ

+0.28%

DBS

DBS

SGD05

DBS Group

DBS Group

USDBSDY

LongbridgeAI